Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

“Best Survival Data Yet” With Nelarabine in T-Cell ALL

December 30, 2021

Kimberly P. Dunsmore, MD, discusses results from the largest trial conducted of young patients with newly diagnosed T-cell acute lymphocytic leukemia, which produced survival rates of 80% to 90%.

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
November 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals